Stock Events

Stock Events

Enlivex Therapeutics 

$2.41
36
-$0.41-14.56% 06:10 Today

Statistics

Day High
2.42
Day Low
2.41
52W High
7.39
52W Low
0.1712
Volume
130
Avg. Volume
-
Mkt Cap
3.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Dec 7Expected
Q4 0
Q3 2025
Q1 2026
Next
-4.48
-3.03
-1.57
-0.12
Expected EPS
-4.48
Actual EPS
N/A

Financials

-Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
0Revenue
1.24BNet Income

Analyst Ratings

$80.00Average Price Target
The highest estimate is ⁦80.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENLV.BOATS. It's not an investment recommendation.
Amazon
8
AMZN
Apple
7
AAPL
Tesla
7
TSLA
NVIDIA
6
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mesoblast
MESO
Mkt Cap1.83B
Mesoblast Limited focuses on the development of regenerative medicine, which competes directly with Enlivex's cell therapy approach for inflammatory conditions.
Fate Therapeutics
FATE
Mkt Cap277.98M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, directly competing with Enlivex's immunotherapy treatments.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is a gene editing company that competes in the broader field of genetic and cell therapies, potentially targeting similar diseases as Enlivex.
Novartis
NVS
Mkt Cap268B
Novartis AG, through its advanced cell therapy platforms, competes in developing treatments for inflammatory and autoimmune diseases, similar to Enlivex's focus areas.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, with its cell therapy and immunology portfolio, competes in the same therapeutic areas as Enlivex, particularly in treatments for inflammatory and autoimmune diseases.
Allogene Therapeutics
ALLO
Mkt Cap518.24M
Allogene Therapeutics is developing allogeneic CAR T cell therapies, which could compete with Enlivex's cell-based therapies for cancer and immune disorders.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other innovative treatments for rare genetic diseases, competing with Enlivex's focus on severe and life-threatening conditions.

About

Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.
Show More
CEO
ISIN
IL0011319527

Listings

STU
DE
1BT.STU
F
DE
1BT.F
XNAS
US
ENLV
BOATS
BOATS
ENLV.BOATS

0 Comments

Share your thoughts

FAQs

What is Enlivex Therapeutics stock price today?▼
The current price of ENLV.BOATS is $2.41 USD — it has decreased by -14.56% in the past 24 hours. Watch Enlivex Therapeutics stock price performance more closely on the chart.
What is Enlivex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Enlivex Therapeutics stocks are traded under the ticker ENLV.BOATS.
What is Enlivex Therapeutics market cap?▼
Today Enlivex Therapeutics has the market capitalization of 3.69M
When is the next Enlivex Therapeutics earnings date?▼
Enlivex Therapeutics is going to release the next earnings report on December 7, 2026.
What were Enlivex Therapeutics earnings last quarter?▼
ENLV.BOATS earnings for the last quarter are -0.31 USD per share, whereas the estimation was -0.3 USD resulting in a -3.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enlivex Therapeutics revenue for the last year?▼
Enlivex Therapeutics revenue for the last year amounts to 0 USD.
What is Enlivex Therapeutics net income for the last year?▼
ENLV.BOATS net income for the last year is 1.24B USD.
In which sector is Enlivex Therapeutics located?▼
Enlivex Therapeutics operates in the Other sector.
When did Enlivex Therapeutics complete a stock split?▼
The last stock split for Enlivex Therapeutics was on October 27, 2026 with a ratio of 1:16.